TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04274335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Description: 1 gram of tranexamic acid to be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Oral Solution
Description: 4 grams of tranexamic acid given as an oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product
Description: 1 gram of tranexamic acid given as 2 separate intramuscular injection
Study: NCT05565430

Intervention type: OTHER
Intervention: Chronic hyperventilation
Description: Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Intervention type: OTHER
Intervention: Chronic hyperventilation
Description: Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Intervention type: OTHER
Intervention: Chronic hyperventilation
Description: Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.

Intervention type: DRUG
Intervention: Effects of anticholinergic medication
Description: Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.

Intervention type: DRUG
Intervention: Effects of anticholinergic medication
Description: Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.

Intervention type: DRUG
Intervention: Effects of anticholinergic medication
Description: Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
Study: NCT02585778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statins at stable, maximally tolerated dose with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statins at stable, maximally tolerated dose with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic Drug
Description: Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihyperglycemic Drug
Description: Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.
Study: NCT00783055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individually tailored programmes
Description: Individualised intervention programmes based on individual wishes for daily activities
Study: NCT01478490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: oral
Study: NCT02802813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)
Study: NCT04446273

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-Manu-Track
Description: The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Manu-Track
Description: The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
Study: NCT02716402

Intervention type: RADIATION
Group type: OTHER
Intervention: Cerebral MRI and V/Q SPECT/CT
Description: Cerebral MRI and V/Q SPECT/CT
Study: NCT02316106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: 16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: 16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: 16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
Study: NCT00195117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
Study: NCT04467216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training using virtual reality
Description: Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
Study: NCT03338608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Decompression and Fusion
Description: Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Decompression and Fusion
Description: Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Platysma Incision
Description: A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse Platysma Incision
Description: A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
Study: NCT02986321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: Dose response: Test one of 4 different doses of CHF6001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: Dose response: Test one of 4 different doses of CHF6001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: Dose response: Test one of 4 different doses of CHF6001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Description: Dose response: Test one of 4 different doses of CHF6001
Study: NCT02802813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo
Study: NCT03352687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior SSAX
Description: block of the suprascapular nerve block for shoulder surgery by anterior way

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior SSAX
Description: block of the suprascapular nerve block for shoulder surgery by posterior way
Study: NCT01363596

Intervention type: OTHER
Intervention: Creighton Model System in conjunction with Natural Procreative Technology (NPT)
Description: Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
Study: NCT02418468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg capsules for inhalation daily
Study: NCT02163057

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: INO-3112
Description: 1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.
Study: NCT02418468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo indacaterol capsules for inhalation daily
Study: NCT03348696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone tapering dose
Description: dexamethasone standard of care pre-medication + dexamethasone tapering dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone physician choice
Description: Dexamethasone standard of care pre-medication + dexamethasone physician choice
Study: NCT02986321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: active control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo control
Study: NCT02302196

Intervention type: PROCEDURE
Intervention: Autologous Fat Grafting of the Breast
Description: In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
Study: NCT02163057

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: INO-3112
Description: 1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.
Study: NCT05192902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Local Anaesthesia
Description: Conventional dental local anaesthetic injections.
Study: NCT02751125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCP with autologous mesenchymal stem cells (MSC).
Description: Augmentation of narrow alveolar ridge with BCP and MSC
Study: NCT03833687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profhilo®
Description: Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
Study: NCT00814268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg tablet, oral administration once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel placebo
Description: Matching tablet, oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100mg tablet, oral administration once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg tablet, oral administration once daily
Study: NCT02302196

Intervention type: OTHER
Intervention: Control Arm
Description: Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
Study: NCT04139824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanthine Oxidase Inhibitor
Description: LC350189 200mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonsteroidal anti-inflammatory drug
Description: Naproxen 500mg BID
Study: NCT03593031

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office Based Vergence and Accommodative Therapy
Description: Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Office Based Vergence and Accommodative Therapy
Description: Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office Based Vergence and Accommodative Therapy
Description: Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Office Based Vergence and Accommodative Therapy
Description: Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
Study: NCT02233010

Intervention type: OTHER
Intervention: The level of NGAL after pre op,post op 4hr, post op 12hr

Intervention type: OTHER
Intervention: The level of NGAL after pre op,post op 4hr, post op 12hr
Study: NCT04146064

Intervention type: OTHER
Intervention: Breathprint analysis and patient-reported outcomes
Description: Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints.
Study: NCT04115020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone 4.5 mg oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone 4.5 mg oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral suspension
Study: NCT01390727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device-guided breathing (Resperate - InterCure, Israel)
Description: After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listen music
Description: After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
Study: NCT01042431

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT00257400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: Interpersonal Psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Psychotherapy
Description: Individual Psychotherapy
Study: NCT04146064

Intervention type: OTHER
Intervention: Breathprint analysis and patient-reported outcomes
Description: Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints.

Intervention type: OTHER
Intervention: Breathprint analysis and patient-reported outcomes
Description: Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints.

Intervention type: OTHER
Intervention: Breathprint analysis and patient-reported outcomes
Description: Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints.

Intervention type: OTHER
Intervention: Breathprint analysis and patient-reported outcomes
Description: Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints.
Study: NCT02142127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labelled GFT505 120 mg
Study: NCT03023865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged stress function
Description: A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
Study: NCT01110746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viaject 7
Description: 100IU/mL administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISPRO
Description: 100IU/mL administered subcutaneously
Study: NCT04126395

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement Assessment Battery for Children 2(M-ABC-2)
Description: The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement Assessment Battery for Children 2(M-ABC-2)
Description: The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement Assessment Battery for Children 2(M-ABC-2)
Description: The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Coordination Disorder - Questionnaire (DCD-Q)
Description: The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Coordination Disorder - Questionnaire (DCD-Q)
Description: The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Developmental Coordination Disorder - Questionnaire (DCD-Q)
Description: The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Social Responsiveness Scale 2 (SRS-2)
Description: The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Social Responsiveness Scale 2 (SRS-2)
Description: The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
Study: NCT03105518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.5, 1 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Single + Oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: With Acetaminophen
Study: NCT03068117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Early Specialist Symptom Control Treatment (RESSCT)
Description: Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death.
Study: NCT02765256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 400mg orally once daily (Day 1-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 500mg oral suspension 4 times daily (Day 1-14)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin
Description: 500mg oral suspension 4 times daily (Day 1-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: neomycin 1000 mg orally three times daily (Days 1-3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neomycin
Description: neomycin 1000 mg orally three times daily (Days 1-3)